Valuation dashboard for PureTech Health plc (PRTC) with P/E N/A, P/B 0.13, EV/EBITDA -42.07 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others.
Analysis Summary
PureTech Health plc reported revenue of $4.7M in the most recent fiscal year, growing at a 5-year CAGR of -11.0%.
Trailing-twelve-month margins: gross margin -471.2%, operating margin -21.2%, net margin -23.6%.
At the current price of $17.38, PRTC has negative trailing earnings (P/E not meaningful) and an ROE of -31.83%. Market capitalisation stands at $4.2B.
Balance sheet quality for PRTC: current ratio of 6.6. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.13 |
| EV / EBITDA | -42.07 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $99.47 |
| vs Current Price | +472.3% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PRTC | PureTech Health plc | $4.2B | 0.13 | -31.8% | |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.3B | 9.75 | -13.5% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% |
Price
| Price | $17.38 |
| Market Cap | $4.2B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -31.83% |
| Return on Invested Capital | -19.64% |
| Return on Assets | -20.48% |
| Gross Margin | -471.15% |
| Operating Margin | -2115.41% |
| Net Margin | -2355.50% |
Related companies: CLYM · GNTA · INBX · IVA · KROS · SLN · TARS
Explore sector: Healthcare · Biotechnology
More sections of PRTC: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks